



GOVERNMENT OF PAKISTAN
(CABINET DIVISION)
INTELLECTUAL PROPERTY ORGANIZATION
THE PATENT OFFICE
KARACHI



To,

Dated: 21-04-2009

Mr. Munir Ahmed,
Director (Admn.),
IPO-Pakistan,
Islamabad.

**Subject: WEEKLY NOTIFICATION OF PATENT OFFICE FOR THE
WEEKENDING 10-04-2009 TO BE PUBLISHED 22-04-2009 IN THE
GAZETTE OF PAKISTAN PART-V.**

Sir,

Reference to IPO letter dated 12-5-2008 forwarding therewith copy of letter No 18/IPO/2008/ RA-IV dated 23-4-2008 from Cabinet Division on the above subject.

A manuscript copies of the weekly notification regarding application filed, application accepted and sealing fee due is enclosed herewith for onward transmission to the Cabinet Division for Publication in the next issue of the Gazette of Pakistan (Part –V)

(Mrs. Yasmeen Abbasi)
Controller of Patents
Ph: 9215488

ENCL:

NEW APPLICATIONS FOR THE PATENTS

The dates shown in the crescent brackets are the dates claimed under section 86 of the Patents Ordinance 2000

287/2009	<u>06-04-2009</u> Engr. Ovais Iqbal, Engr. Adil Ayub, Engr. Yousuf Tariq, Engr. Ashab Mirza, Karachi-Pakistan.	“Smart data acquisition card” or simply “Smart DAQ”
288/2009	Bayer Cropscience AG., Germany (Priority 07-04-2008 USA)	“Combination of biological control agents and insecticides or fungicides”
289/2009	Bayer CropScience LP, USA (Priority 07-04-2008 USA)	“Stable aqueous spore-containing formulation”
290/2009	<u>07-04-2009</u> JDS Uniphase Corporation, USA (Priority 08-04-2008 USA)	“Improved OVD containing device”
291/2009	Areana Pharmaceuticals, Inc., USA (Priority 07-04-2008 USA)	“Methods of using A G protein- coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY”
292/2009	<u>07-04-2009</u> Ghulam Abid Chaudhary, Lahore, Pakistan	“Water based wax shoe polish”
293/2009	IRM LLC, Bermuda (Priority 07-04-2008 USA)	“Compounds and compositions as kinase inhibitors”
294/2009	Infinity Pharmaceuticals, Inc., USA (Priority 09-04-2008 USA)	“Inhibitors of fatty acid amide hydrolase”
295/2009	Reckitt Benckiser (Australia) Pty Limited, Australia (Priority 07-04-2008 UK)	“Mousetrap”

296/2009	N.V. Organon, Netherland Pharmacopeia, LLC, USA (Priority 09-04-2008 USA)	“Pyrrolo[2,3-D]pyrimidin-2-yl-amine derivatives as PKC-theta inhibitors”
	<u>08-04-2009</u>	
297/2009	Bayer BioScience N.V., Belgium Bayer CropScience AG, Germany (Priority 14-04-2008 Europe)	“New mutated hydroxyphenylpyruvate dioxygenase, DNA sequence and isolation of plants which are tolerant to HPPD inhibitor herbicides”
298/2009	Galaxy Biotech, LLC, The Johns Hopkins University USA Kennedy Krieger Institute, Inc. USA (Priority 11-04-2008 USA)	“Combination of HGF inhibitor and EGF inhibitor to treat cancer”
299/2009	Galaxy Biotech, LLC, USA University of Virginia Patent Foundation, USA (Priority 11-04-2008 USA)	“Combination of HGF inhibitor and pten agonist to treat cancer’s
300/2009	Pierre Fabre Medicament, France (Priority 11-04-2008 France)	“Novel antibodies useful for the cancer treatment”
301/2009	Theravance, Inc., USA (Priority 07-04-2004 USA) Divisional.	“A pharmaceutically acceptable salt of quinolinone carboxamide compound”
	<u>09-04-2009</u>	
302/2009	Janssen Pharmaceutica N.V., Belgium (Priority 11-04-2008 USA)	“Thiazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene A4 hydrolase”
303/2009	Glaxo Group Limited, United Kingdom (Priority 11-04-2008 GB)	“Anhydrous crystal form of orvepitant maleate”

SEALING FEES DUE

Notice is hereby given that the Patent may now be sealed on the application referred to below if it is desired that Patent should be sealed a request on the prescribed Form-10 accompanied by the fee of Rs.2250/- should be sent to the Controller of Patents and Designs, The Patent Office, Karachi.

139804	Novartis AG. Switzerland.	493/2000
139805	Novartis AG. Switzerland	402/2002
139806	Agouron Pharmaceuticals, Inc. USA	518/2002
139807	Smithkline Beecham Corporation, USA	449/2003
139808	Boehringer Ingelheim International GmbH. Germany	149/2005
139809	Saudi Basic Industries Corporation. Saudi Arabia	195/2005
139810	Glaxo Group Limited. Great Britain	15/1999
139811	Glaxo Group Limited. Great Britain	845/2006

(MRS. YASMEEN ABBASI)
CONTROLLER OF PATENTS
Tel: 9215488